1. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA (1986) High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer response, treatment-related morbidity and histological finding. JAMA 256:3117–3124
2. Pizza G, Viaz D, Devince C, Vichi-Pascuuchi JM, Busutti L, Bergami T (1988) Intralymphatic administration of interleukin-2 (IL-2) in cancer patients: a pilot study. Cancer Res 7:46–48
3. Sama G, Collins J, Figlin R, Robertson P, Altrock B, Abels R (1990) A pilot study of intralymphatic interleukin-2 II clinical and biological effects. J Biol Response Modif 9:81–86
4. Zinzani PL, Lauria F, Salvucci M, Rondelli D, Raspadori D, Bendandi M, Magagnoli M, Tura S (1997) Hairy-cell leukemia and alpha-interferon treatment: long-term responders. Hematoligica 88:152–155
5. Ozer H, Wiernik PH, Giles F, Tendler C (1998) Recombinant interferon-alpha therapy in patients with follicular lymphoma. Cancer 82:1821–1830